4 recruiting, 4 unknown, 3 not yet recruiting, 1 terminated. 7 Phase 1, 5 Phase 2, 1 Not applicable, 1 Phase 3.
Follow Multiple Myeloma Progression: new trials by email Literature Review of Multiple Myeloma Progression trials Research Report on Multiple Myeloma Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-23 | |
| Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. Teclistamab (Tec) and Pomalidomide (Pom) - Multiple Myeloma Progression | Phase 2 | Not yet recruiting | Odense University Hospital | 50 | 2026-09-01 | 2026-08-11 |
| Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) Allogeneic, off-the-shelf CAR-T cell injection targeting BCMA and GPRC5D - Multiple Myeloma Refractory, Multiple Myeloma Progression | Phase 1 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 16 | 2026-06-01 | 2026-06-03 |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma KLN-1010 - Multiple Myeloma in Relapse, Myeloma Multiple | Phase 1 | Recruiting | Kelonia Therapeutics, Inc. | 70 | 2025-07-16 | 2026-08-28 |
| Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma BCMA/GPRC5D CAR-T cells - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-04-29 | 2025-06-22 |
| CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study Blood draw for the laboratory assessment - Multiple Myeloma, Multiple Myeloma Progression | Recruiting | Wake Forest University Health Sciences | 1665 | 2025-03-01 | 2026-07-13 | |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors 225Ac-DOTATATE - Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | Jules Bordet Institute | 2024-10-01 | 2025-01-31 | |
| Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma Early Palliative Care - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Not applicable | Recruiting | University Health Network, Toronto | 144 | 2024-07-18 | 2025-12-03 |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma Rivaroxaban, ASA - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 / Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 57 | 2019-01-17 | 2024-02-29 |
| Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM anti-CD19/BCMA CAR-T cells, Fludarabine, Cyclophosphamide - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 | Unknown | Peng Liu | 20 | 2018-10-30 | 2018-10-16 |
| Tinostamustine Conditioning and Autologous Stem Cell Tinostamustine, Autologous Stem Cell Transplant (ASCT) - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 / Phase 2 | Terminated | Mundipharma-EDO GmbH | 6 | 2018-10-15 | 2021-06-18 |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Pomalidomide - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 | Unknown | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 18 | 2018-09-01 | 2018-11-14 |
| CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma CAR-T Re-treatment - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 20 | 2018-07-26 | 2018-12-14 |
Multiple Myeloma (10) · Autoimmune Diseases (1) · Blood Protein Disorders (1) · Disease (1) · Disease Progression (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoproliferative Disorders (1) · Monoclonal Gammopathy of Undetermined Significance (1) · Neoplasms (1)
Cardiovascular Diseases (10) · Hemic and Lymphatic Diseases (10) · Hemorrhagic Disorders (10) · Blood Protein Disorders (9) · Hematologic Diseases (9) · Hemostatic Disorders (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Plasma Cell (9) · Paraproteinemias (9) · Vascular Diseases (9) · Lymphatic Diseases (3)
Cyclophosphamide (2) · pomalidomide (2) · Aspirin (1) · Blood Specimen Collection (1) · Dexamethasone (1) · Focal Adhesion Protein-Tyrosine Kinases (1) · Rivaroxaban (1) · fludarabine (1) · tinostamustine (1)
Odense University Hospital (2) · Essen Biotech (1) · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1) · Jules Bordet Institute (1) · Kelonia Therapeutics, Inc. (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mundipharma-EDO GmbH (1) · Peng Liu (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1) · University Health Network, Toronto (1) · Wake Forest University Health Sciences (1) · Zhongshan Hospital (Xiamen), Fudan University (1)
China (3) · United States (3) · Canada (2) · Denmark (2) · Norway (2) · Australia (1) · Belgium (1) · Estonia (1) · Finland (1) · Mexico (1) · Switzerland (1)
Breffni Hannon, MB BCh BAO, MMedSci, MCFP (1) · Dagmar Hess (1) · Manisha Bhutani, MD (1) · Martha Louzada, MD (1) · Parameswaran Hari, MD (1) · Peng Liu, M.D. & Ph.D. (1) · Wan-Hong Zhao, MD, PhD (1)
PMID 15189396, PMID 15842354, PMID 18094721, PMID 20637084, PMID 22409262, PMID 23903204, PMID 26986753, PMID 34582035
2018 (1), 2025 (1)